Patents by Inventor Noriaki Gomi
Noriaki Gomi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9540344Abstract: The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (I) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (I) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (III) or a salt thereof with a compound represented by formula (II) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base.Type: GrantFiled: December 5, 2014Date of Patent: January 10, 2017Assignee: KOWA CO., LTD.Inventors: Noriaki Gomi, Tadaaki Ohgiya, Kimiyuki Shibuya
-
Patent number: 9045460Abstract: The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (I) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (I) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (III) or a salt thereof with a compound represented by formula (II) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base.Type: GrantFiled: August 25, 2011Date of Patent: June 2, 2015Assignee: KOWA CO., LTD.Inventors: Noriaki Gomi, Tadaaki Ohgiya, Kimiyuki Shibuya
-
Publication number: 20150087824Abstract: The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (I) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (I) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (III) or a salt thereof with a compound represented by formula (II) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base.Type: ApplicationFiled: December 5, 2014Publication date: March 26, 2015Applicant: KOWA CO., LTD.Inventors: Noriaki GOMI, Tadaaki OHGIYA, Kimiyuki SHIBUYA
-
Publication number: 20130144054Abstract: The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (I) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (I) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (III) or a salt thereof with a compound represented by formula (II) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base.Type: ApplicationFiled: August 25, 2011Publication date: June 6, 2013Inventors: Noriaki Gomi, Tadaaki Ohgiya, Kimiyuki Shibuya
-
Patent number: 8252781Abstract: [Object] It is to provide a novel compound useful for preventing and/or treating diseases that involves 11?-hydroxysteroid dehydrogenase 1 (in particular diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome). [Means to Solve the Object] A 1,2-diazetidin-3-one derivative represented by the following general formula (1) or salt thereof, or their solvate.Type: GrantFiled: October 28, 2009Date of Patent: August 28, 2012Assignee: Kowa Company, Ltd.Inventors: Hisashi Nakashima, Takaaki Araki, Takahisa Ogamino, Noriaki Gomi, Yasushi Kaneko, Kazutoyo Abe, Tadaaki Ohgiya
-
Publication number: 20120122906Abstract: Disclosed is a novel compound which has both angiotensin II receptor antagonist activity and PPAR? activating activity, and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, kidney diseases, arteriosclerosis, inflammatory diseases, type 2 diabetes, diabetic complication, insulin resistant syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. Also disclosed is a pharmaceutical composition which contains the novel compound. Specifically disclosed are: a sulfonamide derivative represented by general formula (I), a salt thereof, or a solvate of the derivative or salt; and a pharmaceutical composition which contains the sulfonamide derivative, a salt thereof, or a solvate of the derivative or salt.Type: ApplicationFiled: August 27, 2010Publication date: May 17, 2012Applicant: KOWA COMPANY, LTD.Inventors: Toru Miura, Kazuhiro Onogi, Noriaki Gomi, Takaaki Araki, Junya Tagashira, Ryohei Sekimoto, Rio Ishida, Hitomi Aoki, Tadaaki Ohgiya
-
Patent number: 8106053Abstract: To find a compound having a tissue fibrinosis-inhibitory activity and a fibrinolytic activity, and to provide a novel compound that is useful for preventing and/or treating tissue fibrinosis diseases (pulmonary fibrosis, renal fibrosis etc.), diseases caused by pathological blood clots such as ischemic heart diseases (myocardial infarction, angina), intraatrial thrombus, pulmonary embolism, deep venous thrombosis, disseminated intravascular coagulation, ischemic cerebral diseases (cerebral infarction, cerebral bleeding) and arteriosclerosis and the like. To provide a pharmaceutical drug comprising a 5-phenyl-3-pyridazinone derivative represented by the following general formula (I): and an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, useful for preventing and/or treating disease conditions or symptoms mediated by plasminogen activator inhibitor-1.Type: GrantFiled: June 19, 2008Date of Patent: January 31, 2012Assignee: Kowa Company, Ltd.Inventors: Noriaki Gomi, Shinji Ina, Kenjirou Yamana, Yoshio Kaneko
-
Publication number: 20100324091Abstract: A pyrazolone derivative represented by formula (I) below: wherein R1 to R3 are the same as defined in claims; or an optical isomer, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is provided. The novel pyrazolone derivative according to the present invention has a PAI-1 production inhibitory activity, a tissue fibrosis inhibitory activity, and a fibrolytic activity, and is effective for preventing and/or treating tissue fibrotic diseases (lung fibrosis, kidney fibrosis, etc.) and diseases of which a pathological thrombus becomes the cause, such as ischemic cardiac diseases (cardiac infarction and angina pectoris), atrial thrombus, lung embolism, deep thrombophlebitis, disseminated intravascular clotting, ischemic brain diseases (brain infarction, brain hemorrhage), and arterial sclerosis.Type: ApplicationFiled: June 23, 2008Publication date: December 23, 2010Applicant: Kowa Company, Ltd.Inventors: Noriaki Gomi, Shinji Ina, Kenjirou Yamana, Yoshio Kaneko
-
Publication number: 20100197698Abstract: To find a compound having a tissue fibrinosis-inhibitory activity and a fibrinolytic activity, and to provide a novel compound that is useful for preventing and/or treating tissue fibrinosis diseases (pulmonary fibrosis, renal fibrosis etc.), diseases caused by pathological blood clots such as ischemic heart diseases (myocardial infarction, angina), intraatrial thrombus, pulmonary embolism, deep venous thrombosis, disseminated intravascular coagulation, ischemic cerebral diseases (cerebral infarction, cerebral bleeding) and arteriosclerosis and the like. To provide a pharmaceutical drug comprising a 5-phenyl-3-pyridazinone derivative represented by the following general formula (I): and an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, useful for preventing and/or treating disease conditions or symptoms mediated by plasminogen activator inhibitor-1.Type: ApplicationFiled: June 19, 2008Publication date: August 5, 2010Applicant: KOWA COMPANY, LTD.Inventors: Noriaki Gomi, Shinji Ina, Kenjirou Yamana, Yoshio Kaneko
-
Publication number: 20100144694Abstract: [Object] It is to provide a novel compound useful for preventing and/or treating diseases that involves 11?-hydroxysteroid dehydrogenase 1 (in particular diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome). [Means to Solve the Object] A 1,2-diazetidin-3-one derivative represented by the following general formula (1) or salt thereof, or their solvate.Type: ApplicationFiled: October 28, 2009Publication date: June 10, 2010Applicant: KOWA COMPANY, LTD.Inventors: Hisashi Nakashima, Takaaki Araki, Takahisa Ogamino, Noriaki Gomi, Yasushi Kaneko, Kazutoyo Abe, Tadaaki Ohgiya
-
Publication number: 20100022572Abstract: It is to provide a novel compound useful for preventing and/or treating diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome. A spiro compound represented by the following general formula (1) or salt thereof, or their solvate.Type: ApplicationFiled: July 16, 2009Publication date: January 28, 2010Applicant: KOWA COMPANY, LTD.Inventors: Hisashi Nakashima, Takahisa Ogamino, Takaaki Araki, Noriaki Gomi, Yasushi Kaneko, Kazutoyo Abe, Tadaaki Ohgiya, Kimiyuki Shibuya
-
Patent number: 6306853Abstract: A 1,4-dihydropyridine derivative having the formula (I): wherein, R1 represents a substituted or unsubstituted phenyl or pyridyl group, R2 represents a C1 to C5 lower alkyl group, R3 represents a substituted or unsubstituted C1 to C8 alkyl, alkenyl, alkynyl or substituted or unsubstituted C3 to C7 cycloalkyl or cycloalkenyl group, R4 represents —A—R5, wherein A represents a C3 to C5 alkynylene group having one triple bond, and R5 represents a substituted or unsubstituted pyridyl, quinolyl, isoquinolyl or pyrimidyl group and a drug for overcoming resistance to an anti-cancer drug or a drug increasing the effect of an anti-cancer drug containing as an effective ingredient the derivative or its pharmacologically acceptable salt or hydrate.Type: GrantFiled: August 10, 2000Date of Patent: October 23, 2001Assignee: Nikken Chemicals Co., Ltd.Inventors: Shigeyuki Tasaka, Akira Kiue, Hiromasa Omori, Hirokazu Tanabe, Noriaki Gomi